Mount Sinai Joins Test Validation Trial of bioAffinity’s CyPath® Lung

PUBLISHED ON September 22, 2018

SAN ANTONIO, TX (September 18, 2018) bioAffinity Technologies, a privately held biotech company, today announced that the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY, will be a clinical collection site for the Company’s test validation trial of CyPath® Lung, a non-invasive test for the early detection of lung cancer. The study will be performed under the direction of the Clinical Trials Office in the Department of Medicine.

read more

BioAffinity Seeking $5M for Cancer Diagnostic, Adds Board Member

PUBLISHED ON May 18, 2018

(SAN ANTONIO, TX) bioAffinity, the maker of a cancer diagnostic test, has added Peter Knight, who was the chief of staff for Al Gore when he was in Congress, to its board of directors and is in the process of raising a $5 million Series B round of funding, according to CEO Maria Zannes.

read more

bioAffinity Technologies was selected as one of San Antonio’s Top 2020 Innovators. In this video, you will see Maria Zannes, President and Chief Executive Officer, speak about what drives motivation, innovation and success and kick off San Antonio’s premier annual event celebrating the City’s healthcare and bioscience industry.